Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide,
affecting up to 30% of adults. Progression to non-alcoholic steatohepatitis (NASH) is a key …

This concise review article critically examines the recent medical literature regarding gamma
glutamyl transferase (GGT) with a special emphasis on newly proposed indications for GGT …

Importance Several oral antidiabetic drug (OAD) classes can potentially improve patient
outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on …

Abstract Background & Aims The burden of metabolic dysfunction‐associated steatotic liver
disease (MASLD) is growing rapidly, as is the number of older adults globally. However …

Non-alcoholic fatty liver disease (NAFLD) was redefined as metabolic dysfunction-
associated fatty liver disease (MAFLD) in 2020. Due to this, further validation of the non …

Abstract Background and Aim Non‐invasive hepatic steatosis algorithms are recommended
in detecting metabolic‐associated fatty liver disease (MAFLD) in epidemiological studies …

The association between nonalcoholic fatty liver disease (NAFLD) and incident dementia
remains unclear. This study aimed to explore whether NAFLD was associated with the risk of …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a condition characterized by
liver fat accumulation and metabolic abnormalities. Given the potential impact of MAFLD on …

Metabolic dysfunction‐associated steatotic liver disease (MASLD) typically presents with
hepatic fibrosis in advanced disease, resulting in increased liver stiffness. A subset of …

Abstract Background and Aims Sex steroid hormones and sex hormone‐binding globulin
(SHBG) have a role in predisposing individuals to nonalcoholic fatty liver disease (NAFLD) …